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ABSTRACT 
Objective: To develop and validate a prognostic model for incident radiologic hip osteoarthritis 
(HOA) and determine the value of previously identified predictive factors.  
Design: We first validated previously reported predictive factors for HOA by performing 
univariate and multivariate analyses for all predictors in 3 large prospective cohorts (total 
sample size of 4548 with 653 incident cases). The prognostic model was developed in 2327 
individuals followed for 10 years from the Rotterdam Study-I (RS-I) cohort. External validation 
of the model was tested on discrimination in two other cohorts: RS-II (n=1435) and the Cohort 
Hip and Cohort Knee (CHECK) study (n=786). 
Results: From the total number of 28 previously reported predictive factors, we were able to 
replicate 13 factors, while 15 factors were not significantly predictive in a meta-analysis of the 3 
cohorts. The basic model including the demographic, questionnaire, and clinical examination 
variables (area under the curve (AUC)=0.67) or genetic markers (AUC=0.55) or urinary C-
terminal cross-linked telopeptide of type II collagen (uCTX-II) levels (AUC=0.67) alone were poor 
predictors of HOA in all cohorts. Imaging factors showed the highest predictive value for the 
development of HOA (AUC=0.74). Addition of imaging variables to the basic model led to 
substantial improvement in the discriminative ability of the model (AUC=0.78) compared with 
uCTX-II (AUC=0.74) or genetic markers (AUC=0.68). Applying external validation, similar results 
were observed in the RS-II and the CHECK cohort. 
Conclusions: The developed prediction model included demographic, a limited number of 
questionnaire, and imaging risk factors seems promising for prediction of HOA.  
Keywords: osteoarthritis, prediction, Hip, risk 
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INTRODUCTION 
The number of people affected with osteoarthritis (OA) is likely to increase due to the high 
prevalence of obesity and ageing of the population whilst, to date, there are no curative 
treatment options which allow regeneration of damaged cartilage (1,2). The current focus in OA 
research and clinical practice is on persons with radiographic symptomatic disease (3). Despite 
extensive researches, modern therapies are largely palliative and only modestly effective. There 
is presently no disease-modifying osteoarthritis drug with a consistent, documented effect 
despite several clinical attempts in late-stage phases. This reinforces the need for interventions 
in early OA or even before development of symptoms to develop preventive strategies (3). 
Therefore, clinicians have the challenging task to identify those individuals that will develop OA 
as early as possible. Identification of high-risk individuals will be beneficial for efficient 
screening of novel therapeutic options, since follow-up time and number of individuals included 
in the studies can be reduced when only subjects are included which are at a high risk of 
developing OA. 
Conventional risk prediction models, although well established in other disease areas, such as 
cardiovascular disease, have not been developed in OA and in particular not for hip OA. Two 
recent studies reported on prediction models for incidence and progression of knee OA (4,5). In 
the first study (4), three different models were evaluated for incident and progressive 
radiographic knee OA and symptomatic knee OA among a small high-risk cohort of 99 cases and 
179 controls with 12 years of follow-up using conventional risk factors such as age, gender, 
body mass index (BMI), family history of OA, occupational risk, and joint injury. However, 
external validation of these models in the Osteoarthritis Initiative showed poor discrimination. 
In another study among Rotterdam Study (RS) participants (5), different risk prediction models 
were developed using basic risk factors (i.e., age, gender and BMI) and were compared with 
less conventional risk factors such as radiographic features, genetic risk score, and biochemical 
marker of urinary C-terminal cross-linked telopeptide of type II collagen (uCTX-II) levels. They 
showed that all risk factor groups by themselves had limited and rather similar predictive value, 
while the full model had useable predictive value and showed good external validation.  
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In the current study, we focus on prediction of incident hip OA. A recent review highlighted the 
fact that hip OA requires specific attention separate from other OA phenotypes, since its 
etiology is different from knee OA (6). Surprisingly very little prospective data on hip OA is 
available, since the majority of risk factor assessment has been done on cross-sectional data. In 
addition, no study has tried to make a prediction model for hip OA using multiple risk factors, 
something that was recently highlighted to be essential for future monitoring and managing of 
hip OA patients (6). In the current manuscript, we therefore aimed to determine the value of 
various sets of risk factors, which were selected based on previous literature. These included 
anthropometric /demographic characteristics, routine questionnaire and clinical examination 
parameters, imaging risk markers, biochemical marker of uCTX-II, and genetic markers in hip OA 
risk prediction. We attempted to validate the previously suggested risk factors for hip OA in 3 
large prospective cohorts, and then used that information to develop and validate a prognostic 
model for incident hip OA. We used the first cohort of the large prospective population-based 
Rotterdam Study (RS-I) to develop the risk prediction model. The model was externally 
validated in the second cohort of the Rotterdam Study (RS-II), which is an independent cohort 
with similar population characteristics, and the Cohort Hip and Cohort Knee (CHECK) study, 
which is a study of people who for the first time consult the general practitioner for their joint 
complaints. Our study is the first to compare the value of different risk factor groups including 
the clinical, imaging, genetic, and biochemical markers in prediction of hip OA and provides the 
first risk prediction model for incident hip OA. 
METHODS  
Study populations 
The Rotterdam Study is a large prospective population-based cohort study of men and women 
aged 55 years and older in the municipality of Rotterdam, the Netherlands. The study design 
and rationale are described elsewhere in detail (7). The first cohort (RS-I) was initiated in 1989 
and included 7983 individuals. The second cohort (RS-II) was initiated in 2000 and included 
3011 inhabitants who reached the age of 55 years after the baseline examination and persons 
aged 55 years or older who migrated into the research area. Written informed consent was 
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obtained from all participants and the study was approved by the Medical Ethics Committee of 
the Erasmus Medical Center (7). Baseline measurements were obtained through a home 
interview and visits to the research center for physical examinations and imaging and 
laboratory assessments. The present study includes the cohort’s participants for whom hip 
radiographs at baseline and 10 years follow-up were present and scored. Patients with 
ankylosing spondylitis, rheumatoid arthritis (RA), and subjects with a total hip replacement 
(THR) due to fracture were excluded from the study. After these exclusions, 2327 participants 
from RS-I were used to develop the risk prediction model and 1435 participants from RS-II were 
used for external validation of the model (Figure 1). 
The CHECK study included 1002 participants aged 45-65 years living in The Netherlands, with 
early symptomatic OA characterized by pain of knee and/or hip, entered the cohort in the 
period October 2002 to September 2005. They were included at or within 6 months of their first 
visit to the general practitioner for these symptoms (8). Participants with a pathological 
condition that could explain the hip symptoms were excluded including intra-articular fractures, 
RA, congenital dysplasia, Perthes disease, subluxation, osteochondritis dissecans, septic 
arthritis, previous hip joint replacement, previous hip surgery, and individuals having only 
symptoms of bursitis or tendinitis. This left 786 participants with 8 years follow-up from the 
CHECK study for external validation of the risk prediction model (Figure 1). 
Outcome assessment 
Weight-bearing antero-posterior radiograph of the pelvis was obtained at baseline and follow-
ups and scored for the presence of a THR and OA according to the K&L score (9). Radiographic 
hip OA was defined as a K&L score≥2 of one or both joints or a THR. The incidence of hip OA 
was defined as a K&L<2 at baseline and THR or K&L≥2 at follow-up. All subjects were free of hip 
OA in both side at baseline. 
Risk factors  
Previously suggested hip OA risk factors or predictors that were available in RS were included in 
the study. These include age, obesity (BMI and waist to hip ratio (WHR)), gender, height, family 
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history of OA, occupation, smoking, education, alcohol intake, diabetes, high blood pressure, 
joint pain (hip, knee, low back), hip joint morning stiffness, lower limb disability index, and 
baseline measurement of total cholesterol, high-density lipoprotein cholesterol level (HDL), and 
C reactive protein (CRP),  hip baseline K&L score (0 or 1), hand OA divided as finger OA and 
thumb OA, subtle acetabular dysplasia, cam morphology, femoral neck bone marrow density at 
baseline, urinary CTX-II, and a genetic risk score (Supplementary Table 1). The Supplementary 
Material describes the methods for measuring all of the risk predictors. 
Statistical analysis 
Age and sex adjusted generalized estimating equation (GEE) model (a logit model) was used to 
evaluate the association between the predictive factors and hip OA incidence within each 
cohort , followed by a meta-analyses of the results.     
Development of the Risk Prediction Model 
GEE model was used to fit the models for correlations between the right and left extremity in 
each individual using RS-I cohort. Using a backward elimination, we made a basic model that 
included the demographic, questionnaire, and clinical and routine laboratory examination 
variables. The variable that was least significant was removed and the model was refitted. Each 
subsequent step removed the least significant variable in the model until all remaining variables 
had individual P-values smaller than 0.10. To determine the added prediction value of the 
predictors which generally are not used in the routine clinical examination, the basic model was 
extended by the addition of the imaging risk factors, uCTX-II, and genetic risk score, separately 
and combined. We, therefore, constructed 5 models; (1) the basic model, (2) the basic model + 
imaging variables, (3) the basic model + uCTX-II levels, (4) the basic model+ genetic markers, 
and (5) the basic model + imaging variables + uCTX-II levels. Assessment of the predictive 
discrimination of the various models was made using ROC curve by plotting the sensitivity 
against the corresponding false-positive rate. The AUC was used as a measure of how well a 
group of variables predicted the development of hip OA. AUC was corrected for optimism by 
100 bootstrap repetitions (Supplementary Material). The models were developed for 10-year 
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hip OA risk prediction. As some risk factors might be more predictive for the Hip OA occurring in 
a shorter time period, we further repeated all models using 5 years follow-up. 
External Validation 
Calibration and discrimination abilities of the models were externally examined in two cohorts: 
(1) RS-II which is an independent cohort with similar population characteristics; (2) CHECK 
cohort which is a high risk population (details in Supplementary Material). All analyses were 
performed using SPSS (IBM SPSS Statistics 21) and R, version 3.3.3. 
RESULTS 
The baseline characteristics of all three studies are shown in Table 1. In total, 2327 individuals 
from RS-I with both radiographic examinations at baseline and follow-up were included in the 
model development. The RS-I participants had mean age of 64 years (SD=5.8), 56.3% women, 
mean BMI of 26.2 (SD=3.5), and mean follow-up of 10.8 years (SD=1.1). Incident hip OA was 
seen in 7% of the hips. Participants of the RS-II and CHECK cohorts were younger than the RS-I 
cohort. The proportion of diabetics and smokers were higher in RS-II. The CHECK cohort 
included the highest percentage of female participants and OA incidence, while RS-I subjects 
had the highest frequency of K&L score of one at baseline. Hip pain, cam morphology and 
dysplasia were more frequent in CHECK participants. Around half of the RS-I and RS-II subjects 
dropped out, because no follow up radiograph was available (Figure 1). These subjects were 
older, less educated, more frequently smoking and disabled, and had higher level of CRP and 
more hip pain compared to the subjects with follow-up radiograph. Compared to the total 
cohort of RS-I and RS-II, included study subjects were younger, less diabetic, more educated, 
and had lower CRP levels and less hip pain (data not shown). The genetic risk scores were 
normally distributed (Supplementary Figure 1) in all cohorts and was higher in CHECK cohort 
compared with RS-I and RS-II.  
Since many of the previously identified risk factors have not been validated to a large extent in 
longitudinal prospective cohorts, we first set out to determine the relationship between these 
factors and incident hip OA; these results are shown in Supplementary Table 3-6. We found a 
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significant negative association between physically demanding work and hip OA incidence 
which could be due to a health-based selection bias (Supplementary Table 6). Therefore this 
variable was excluded from our analyses. We confirmed a number of previously reported risk 
factors (age, height, WHR, hip pain, LLD, diabetes, CRP and uCTX-II level, BMD, presence of 
thumb OA, hip dysplasia and cam morphology, and doubtful mild degenerative changes in hip 
joint (K&L=1)), but did not observe a significant association with incident hip OA for the 
following reported factors: female gender, BMI, alcohol intake, education, smoking status, pain 
in knee and low back, hip stiffness, presence of HBP, hypercholesterolemia and finger OA, 
positive family history of osteoarthritis, and genetic markers (Supplementary Table 6). 
For comparison of the discriminative ability of different sets of risk factors for hip OA risk 
prediction, we used the AUC. A total of five different groups of risk factors were created; (1) 
age, sex, and BMI, (2) all questionnaire, clinical examination variables, and routine lab test, (3) 
uCTX-II level, (4) imaging variables, (5) genetic risk score. The results are shown in 
Supplementary Table 7. The first three groups showed a poor prediction ability for incident hip 
OA (AUC range 0.60-0.67) while imaging variables showed the highest AUC (0.74). The genetic 
risk score had no discriminative ability for prediction of 10-year incidence of hip OA.  
We then constructed the prediction models. We developed 5 prediction models. The ‘basic 
model’ included demographic, information gathered by questionnaire, and routine lab tests: 
gender, age, BMI, hip pain, education, smoking status, diabetes, family history of OA, and CRP 
level (Table 2). The AUC of the basic model was 0.67 for 10-year hip OA risk prediction. 
Subsequently imaging features were added to the basic model. The imaging variables that 
remained significant in the model included cam morphology, subtle hip dysplasia, presence of 
thumb OA, and baseline hip K&L grade of one. Compared with uCTX-II and genetic markers, 
addition of the imaging markers to the base model showed the highest increase in model 
discrimination (AUC=0.78) (Table 2). Adding the biochemical markers to the model increases 
the predictive value of the model to an AUC of 0.82. However, as the sample size for the last 
model (model 5) was limited (82 cases and 1073 controls, Table 2), the results should be 
interpreted with caution. 
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We checked the interaction of continuous variables with sex and age. None of them was 
significant except a borderline association between sex and uCTX-II. Therefore, no interaction 
term was included in the models. 
The AUC of the different models in external validation cohorts are depicted in Table 3. The basic 
model showed a moderate discriminative ability in RS-II cohort (AUC=0.60, 95% CI=0.56-0.64) 
while in CHECK cohort it showed no discriminative ability (AUC=0.54, 95% CI=0.50-0.58). In both 
RS-II and CHECK cohorts, addition of imaging variables to the basic model provided the highest 
discrimination (AUC=0.75 (0.72-0.79) and 0.71 (0.66-0.75) in RS-II and CHECK cohorts 
respectively). 
Calibration plots of the basic model and the basic model together with uCTX-II in RS-II showed 
reasonable agreement between predicted and actual probabilities while the models including 
imaging variables underestimated the actual probabilities (Figure 2). In the CHECK cohort, all 
models showed a poor calibration. As the CHECK cohort includes a high risk population, this 
systematic underestimation of the risk by the models is expected. 
Analyses for 5 years follow-up showed essentially similar results as 8-10 years follow-up for all 
three cohorts (Supplementary Table 8 and supplementary Figure 2) except that the imaging 
markers showed to be better predictors for 5 years follow-up.  
DISCUSSION 
Osteoarthritis of the hip affects 7%-25% of Caucasian people over the age of 55 years (11). In 
addition to the related pain and discomfort, hip OA has substantial economic consequences, 
and with the current aging of the population in western societies this problem will increase 
(11). An individual risk assessment tool for future OA is needed to develop preventive 
strategies. could be applied. Furthermore, clinical decision making of general practitioners will 
be affected. In addition, a good prediction model could be used in selection of participants for 
trials. We here present the first study to evaluate the predictive values of different risk factor 
groups and to develop a risk prediction model for radiographic hip OA based on conventional 
risk factors, imaging features, biochemical -, and genetic markers. The models were developed 
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in a population-based cohort of elderly people followed for 10 years. The basic model including 
gender, age, BMI, hip pain, education, smoking status, diabetes, family history of OA, and CRP 
level showed limited discriminative value in all cohorts. Among the different groups of 
predictors, imaging factors showed the best predictive value for the development of OA. 
Addition of these variables to the basic model led to substantial improvement in the 
discriminative ability of the model.  
The model with best predictive performance included demographic variables (age, sex, BMI) 
and a limited set of questionnaire/routine lab test variables (diabetes, smoking status, 
educational level, hip pain, positive family history of OA, and CRP level) and imaging risk factors, 
and seems promising for prediction of hip OA. Among the imaging features, doubtful mild 
degenerative changes (defined as a K&L score of one) are important predictors of future 
incident hip OA. As the predictive measure is similar to the outcome measure, a strong 
correlation between this predictive variable and the outcome is expected. In a study using 
incident knee OA data from RS, K&L score of one at baseline also was a strong predictor for 
knee OA development (5). Although radiologists do not always report a K&L score of one, this 
finding may be used by the practitioner and the patient for making decisions regarding 
preventative measures, enrolment in clinical trials for early OA, and monitoring of disease 
progression. Indeed, these minor radiographic changes represent an early stage of OA in which 
some structural damage has already occurred and therefore, the probability of progression to a 
definite OA is higher compared with people without any signs of OA on a radiograph. By 
excluding the baseline K&L score variable from the model, AUC reduced to 0.71. Moreover, our 
results indicated that individuals who have cam-type morphology are at high risk of developing 
osteoarthritis. A cam-type morphology might be a modifiable risk factor that can be diagnosed 
before severe hip damage is present, providing an opportunity to prevent hip osteoarthritis 
(12). 
While our developed risk prediction models provided a reasonable calibration in the second 
cohort of the Rotterdam Study, the calibrations were poor for the CHECK cohort which is a 
clinical cohort of people coming to the general practitioners for the first time with joint 
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complaints. Several differences between populations may affect the results of the validation. 
We found that models including imaging variables showed poor calibration. To explore the 
effect estimates of imaging variables, we applied the same GEE model as discovery in the 
validation cohorts. The results suggest that these variables are stronger predictors for 
participants of the validation cohorts than the RS-I population (the discovery). We observed 
higher estimates for K&L baseline and cam morphology in the RS-II and CHECK cohorts 
compared with RS-I when adjusted for all other variables in the model. Moreover, distribution 
of several variables differed between the development and validation cohorts. We previously 
showed that cam morphology and hip dysplasia increased the risk of hip OA in subjects younger 
than 65 years (13). Therefore, the obtained estimates in RS-I could have resulted in an 
underestimation of the risks in RS-II and CHECK cohorts, which consist of younger participants. 
The CHECK cohort includes a high risk population who at recruitment had pain or stiffness of 
knee or hip joints. So it was expected that a prediction model developed in a general elderly 
population might underestimate the risk in this population.   
Heritability of hip OA has been estimated to be around 40-60% (14,15). However, to date only 
few genetic variants have been successfully identified (14,16,17). Current SNPs used in this 
study are among common variants which explain only a small part of the disease variation. Our 
study did not show large predictive ability for this set of markers for incident of hip OA, which 
might be explained by the limited genetic variants available up to now. In addition, a number of 
genetic variants included in the overall genetic risk score, have previously been found to have 
effects in only a part of the population (for example only in women or men). In a study using 
incident knee OA data from Rotterdam Study, a moderate predictive value of a set of genetic 
markers chosen form literature was seen (AUC=0.62) (5). 
Besides the prediction model, we present prospective data on a total of 28 previously 
suggested risk factors for hip OA. Previous reports on risk modeling has focused exclusively on 
knee OA, while hip OA is also a major form of OA disabling many individuals around the world. 
A recent review specifically highlighted the need to examine risk factors for hip OA separately 
from knee OA (7). We here presented data on a total of 4548 individuals from 3 prospective 
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cohorts on hip OA, and therefore present valuable information for definite validation of these 
factors. We found similar risk estimates for age within each cohort suggesting that aging is the 
robust identified risk factor for the development of hip OA. Our data did not show the 
relationship between sex and hip OA, which was consistent with the results of a recent 
prospective study including more than 3 million people from Spain (18), and was inconsistent 
with the results of a meta-analysis of two old studies showing an increased incidence of hip OA 
in females (19). The different results may relate to different inclusion/exclusion criteria and 
definition of hip OA.  
We could not confirm the association between BMI and hip OA incidence, while WHR that 
shows abdominal obesity was associated with increased risk of hip OA. The latter finding is in 
contrast with the results of two studies (a case-control study and a population based 
prospective cohort study) reported no association between WHR and hip OA arthroplasty 
(20,21). The mechanism of the association between obesity and hip OA traditionally was 
thought to be purely biomechanical. However, recent advances in adipose biology have 
suggested that the adipocytokine, leptin has effects on chondrocytes (20). After adjustment for 
BMI, the risk estimate for WHR although non-significantly, was still high (OR=2.42, 95% CI=0.51-
11.4, p=0.26), even higher than BMI estimate (OR=1.04, 95% CI=1.00-1.07, p=0.05).  
Consistent with our finding, there is evidence that persons with hip or knee OA are more likely 
to have greater BMD than age-matched persons without OA at these sites (2). The contribution 
of high bone density to the pathogenesis of OA might be explained by the fact that OA is a 
process characterized by increased subchondral thickness and bony sclerosis. In contrast, 
progressive OA is often characterized by bony attrition. In the Framingham cohort, risk for 
progressive knee OA decreased from 34.4% to 22.0%, 20.3%, and 18.9% as BMD increased (22). 
Thus, it appears plausible that the bone effects may differ at different stages of the disease (2).  
Strengths of the current study include its large sample size, comparison of multiple markers 
that were all measured with standardized methods, and use of hard end points to avoid 
misclassification bias. This study has several limitations as well. There are a few potentially 
important risk factors for hip OA for which data were not available in our study including hip 
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injury, physical activity, and physical examination of the hips (RS cohort). The studies among 
CHECK participants (23,24) have shown that painful internal rotation of the hip is a good 
predictor of 6 years THR. Moreover, our validation cohorts lacked some of the model variables 
such as family history of OA (RS-II and CHECK), and hand OA (CHECK) which could result in 
underestimation of the predicted probabilities. Second, our study subjects were 55 years or 
older at baseline. At this age, some people already have osteoarthritis and were excluded from 
the study. In addition, we used a subset of RS participants who were able to visit the research 
center at baseline and follow-up. These subjects were younger, more educated and mobile (less 
disability) and survived in the follow-up period. These factors could have led to the relatively 
healthier and younger study population and therefore this may limit the model’s 
generalizability. Moreover, the effect of some risk predictors might be underestimated in our 
prediction models because of the excluded individuals. As the same condition was present for 
included subjects of RS-II, this may partly explain the modest calibration of the models in RS-II 
(lower predicted probabilities).  
In conclusion, a basic model including the demographic, questionnaire, and clinical examination 
variables or model containing a genetic markers or uCTX-II levels alone were not good 
predictors of incident radiographic hip OA. In contrast, a model including the basic model with 
imaging features reached a fair predictive value and might be applicable in clinical practice 
when validated in other studies. The reported models could be seen as pilots to lead further 
research in this area. The models may be applied at the individual level to predict the risk, and 
to encourage risk reduction. 
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Figure 1. Flowchart of participants of RS-I (10 years follow-up), RS-II (10 years follow-up), and 
CHECK cohorts (8 years follow-up) included in the study; rheumatoid arthritis (RA); ankylosing 
spondylitis (AS); osteoarthritis (OA); total hip replacement (THR) 
 
Figure 2. Calibration plots for different models in RS-II and CHECK cohorts; mean predicted 
probability of outcome and mean observed outcome for the basic model, basic + imaging 
variables, basic + CTX-II, and basic + imaging variables + CTX-II were 0.07/0.08, 0.05/0.08, 
0.07/0.08, 0.04/0.08 for RS-II and 0.06/0.19, 0.04/0.19, 0.06/0.19, 0.04/0.19 for CHECK cohort 
respectively.  
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Table 1. Descriptive statistics of the included cohorts 
Model development Model Validation  
 RS-I RS-II CHECK 
Sample size, N 2327 1435 786 
Age*  64.0 (5.80) 61.8 (5.08) 55.8 (5.21) 
Women, % 56.3 55.2 78.6 
BMI, kg/m2 * 26.2 (3.48) 27.2 (3.78) 26.2 (4.02) 
Hip pain, % 7 13.9 39.4 
Diabetes, % 6.1 9 2.9 
Smoking, %   
 
   
         Never 31.9 67.3 31.3 
         Former 46.7 10.5 55 
         Current 21.4 22.2 13.7 
Education, %    
         Low 43.9 49.3 19.7 
         Mediate 44.1 31 52.2 
         High 12 19.7 28.1 
Family history of OA, % 21.8 NA NA 
CRP, mg/l* 2.60 (4.88) 2.17 (3.67) 3.13 (7.58) 
Cam morphology†, % 6.5 5.6 8.8 
Acetabular dysplasia†, % 4 3.8 10.9 
Thumb OA, % 28 17.2 NA 
uCTX-II, ng/mmol* 2.24 (0.21) 2.28 (0.23) 2.26 (0.27) 
K&L score 0 at baseline, N (%)† 2943 (63.2) 2520 (87.8) 1198 (76.2) 
K&L score 1 at baseline, N (%)† 1711 (36.8) 350 (12.2) 374 (23.8) 
Hips with OA incidence, N (%)† 321 (6.9) 222 (7.7) 292 (18.6) 
Hips without OA incidence, N (%)† 4254 (91.4) 2628 (91.6) 1271 (80.9) 
Follow-up time* 10.8 (1.13) 10.3 (0.98) 7.7 (1.16) 
Body mass index (BMI); osteoarthritis (OA); Kellgren and Lawrence (K&L); C reactive protein 
(CRP);* mean (SD); † numbers are based on hips; †Acetabular dysplasia and cam morphology 
were defined as the presence of a center-edge angle <20° and an alpha angle of >60°, 
respectively. 
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Table 2. Multivariate models including different risk factors groups in prediction of incident hip OA in RS-I 
 Basic model (B) (B)+ Imaging variables  (B)+ uCTX-II levels (B)+ genetic markers (B)+ Imaging + uCTX-II 
 OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Age 1.08 (1.05-1.10) <0.0001 1.06 (1.03-1.08) <0.0001 1.09 (1.05-1.14) <0.0001 1.08 (1.06-1.11) <0.0001 1.07 (1.02-1.12) 0.01 
women 1.96 (1.44-2.69) <0.0001 2.41 (1.70-3.41) <0.0001 2.12 (1.20-3.73) 0.01 1.90 (1.36-2.62) 0.0001 3.37 (1.73-6.59) 0.0004 
BMI 1.04 (1.01-1.08) 0.02 1.06 (1.02-1.10) 0.01 0.99 (0.93-1.05) 0.71 1.04 (1.00-1.08) 0.04 1.02 (0.95-1.10) 0.52 
CRP 1.22 (1.00-1.50) 0.05 1.27 (1.01-1.58) 0.04 1.58 (1.12-2.22) 0.01 1.30 (1.06-1.61) 0.01 1.48 (0.96-2.30) 0.08 
Smoking 
    Former 
    Current 
1.04 (0.76-1.43) 
1.52 (1.04-2.23) 
0.07 
0.98 (0.69-1.39) 
1.40 (0.92-2.14) 
0.18 
1.34 (0.75-2.39) 
1.86 (0.91-3.81) 
0.23 
1.12 (0.81-1.58) 
1.56 (1.04-2.35) 
0.11 
1.39 (0.70-2.75) 
1.58 (0.66-3.76) 
0.52 
OA in family 1.32 (0.97-1.78) 0.08 1.27 (0.90-1.80) 0.18 1.58 (0.85-2.92) 0.15 1.36 (0.99-1.86) 0.06 1.82 (0.86-3.85) 0.12 
Diabetes 1.61 (0.98-2.64) 0.06 0.93 (0.49-1.77) 0.84 2.02 (0.93-4.40) 0.08 1.53 (0.90-2.60) 0.11 0.60 (016-2.25) 0.45 
Hip pain 1.52 (1.03-2.23) 0.04 1.48 (0.97-2.25) 0.07 1.83 (0.89-3.78) 0.10 1.65 (1.11-2.47) 0.01 1.47 (0.63-3.43) 0.37 
Education 
    Mediate 
    High 
1.30 (0.98-1.73) 
1.61 (1.03-2.50) 
0.06 
1.08 (0.79-1.49) 
1.51 (0.93-2.46) 
0.25 
1.07 (0.65-1.76) 
0.60 (0.24-1.49) 
0.47 
1.21 (0.89-1.63) 
1.42 (0.88-2.31) 
0.27 
0.88 (0.47-1.59) 
0.62 (0.20-1.94) 
0.66 
Thumb OA   1.78 (1.30-2.44) 0.0003     2.61 (1.44-4.75) 0.002 
Baseline KL score   4.43 (3.41-5.77) <0.0001     3.96 (2.40-6.55) <0.0001 
Hip dysplasia   2.36 (1.44-3.84) 0.001     2.97 (1.06-8.33) 0.04 
Cam morphology   1.84 (1.18-2.87) 0.01     1.96 (0.80-4.79) 0.14 
uCTX-II levels     9.83 (2.76-35.0) 0.0004   5.54 (1.08-28.4) 0.04 
Genetic risk score       1.11 (1.04-1.18) 0.002   
AUC of the model 0.67 (0.64-0.70) 0.78 (0.75-0.81) 0.74 (0.69-0.79) 0.68 (0.64-0.71) 0.82 (0.77-0.86) 
OA/no-OA 321/4254 258/3574 113/1212 293/3904 82/1073 
Urinary C-terminal cross-linked telopeptide of type II collagen (uCTX-II); osteoarthritis (OA); area under the receiver-operating characteristic 
curve (AUC); body mass index (BMI); C reactive protein (CRP); Distribution of most variables was the same for subjects with and without uCTX-II 
data and the drop out did not affect the results. All models were repeated using the same sample size (69 cases and 996 controls) in which the 
data were available for all variables and the conclusions remained same. Model performance was classified according to AUC scores: 0.50-0.60 = 
fail, 0.60-0.70 = poor, 0.70-0.80 = fair, 0.80-0.90 = good, and 0.90-1.0 = excellent.
22 
 
Table 3. Discrimination of the risk prediction models in external validation cohorts  
Model Discrimination: AUC (95% CI) 
 OA/no-OA RS-II 
10 y Follow-up 
OA/no-OA CHECK 
8 y follow-up 
Basic model 222/2628 0.60 (0.56-0.64) 292/1271 0.54 (0.50-0.58) 
Basic model + imaging variables 191/2086 0.75 (0.72-0.79) 230/1003 0.71 (0.66-0.75) 
Basic model + uCTX-II levels 146/1705 0.65 (0.60-0.70) 292/1271 0.61 (0.57-0.65) 
Basic model + genetic markers 189/2037 0.62 (0.58-0.66) 271/1143 0.57 (0.53-0.61) 
Basic model + imaging variables + uCTX-II 135/1566 0.75 (0.71-0.80) 230/1003 0.69 (0.65-0.73) 
AUC, area under the curve; in order to get more robust estimates, the largest sample size for each model was used. 
 
 
 
 
